167 related articles for article (PubMed ID: 8700126)
1. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
Bouchelet I; Cohen Z; Case B; Séguéla P; Hamel E
Mol Pharmacol; 1996 Aug; 50(2):219-23. PubMed ID: 8700126
[TBL] [Abstract][Full Text] [Related]
2. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.
Hamel E; Fan E; Linville D; Ting V; Villemure JG; Chia LS
Mol Pharmacol; 1993 Aug; 44(2):242-6. PubMed ID: 8394988
[TBL] [Abstract][Full Text] [Related]
3. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
[TBL] [Abstract][Full Text] [Related]
4. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery.
Bouchelet I; Case B; Olivier A; Hamel E
Br J Pharmacol; 2000 Feb; 129(3):501-8. PubMed ID: 10711348
[TBL] [Abstract][Full Text] [Related]
5. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization.
Cohen Z; Bouchelet I; Olivier A; Villemure JG; Ball R; Stanimirovic DB; Hamel E
J Cereb Blood Flow Metab; 1999 Aug; 19(8):908-17. PubMed ID: 10458598
[TBL] [Abstract][Full Text] [Related]
6. Evidence for 5-HT1D beta but not 5-HT1D alpha receptor subtype expression in canine large coronary arteries and saphenous vein.
Sgard F; Faure C; Graham D
Cardiovasc Res; 1996 May; 31(5):793-9. PubMed ID: 8763409
[TBL] [Abstract][Full Text] [Related]
7. Dual effect of the serotonin agonist, sumatriptan, on peripheral neurogenic inflammation.
Pierce PA; Xie GX; Peroutka SJ; Levine JD
Reg Anesth; 1996; 21(3):219-25. PubMed ID: 8744664
[TBL] [Abstract][Full Text] [Related]
8. 5-HT1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression.
Verheggen R; Hundeshagen AG; Brown AM; Schindler M; Kaumann AJ
Br J Pharmacol; 1998 Aug; 124(7):1345-54. PubMed ID: 9723944
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats.
Reuter U; Salomone S; Ickenstein GW; Waeber C
Cephalalgia; 2004 May; 24(5):398-407. PubMed ID: 15096229
[TBL] [Abstract][Full Text] [Related]
10. Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.
Rebeck GW; Maynard KI; Hyman BT; Moskowitz MA
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3666-9. PubMed ID: 8170966
[TBL] [Abstract][Full Text] [Related]
11. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs.
Villalón CM; Centurión D; Sánchez-López A; De Vries P; Saxena P
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1057-67. PubMed ID: 11216445
[TBL] [Abstract][Full Text] [Related]
12. Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model.
Knyihár-Csillik E; Tajti J; Samsam M; Sáry G; Slezák S; Vécsei L
J Neurosci Res; 1997 Jun; 48(5):449-64. PubMed ID: 9185668
[TBL] [Abstract][Full Text] [Related]
13. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
Peroutka SJ
Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
[TBL] [Abstract][Full Text] [Related]
14. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
Lesage AS; Wouters R; Van Gompel P; Heylen L; Vanhoenacker P; Haegeman G; Luyten WH; Leysen JE
Br J Pharmacol; 1998 Apr; 123(8):1655-65. PubMed ID: 9605573
[TBL] [Abstract][Full Text] [Related]
15. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Hoskin KL; Goadsby PJ
Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
[TBL] [Abstract][Full Text] [Related]
16. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
17. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
19. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients.
Maassen VanDenBrink A; Vergouwe MN; Ophoff RA; Naylor SL; Dauwerse HG; Saxena PR; Ferrari MD; Frants RR
Am J Med Genet; 1998 Jun; 77(5):415-20. PubMed ID: 9632173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
